Castle Biosciences Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Castle Biosciences Inc 's ROA in the second quarter of 2026?
Castle Biosciences Inc recorded a cumulative net loss of $0 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -0.04%.

However, within the Healthcare sector 212 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 2299, from total ROA ranking in the first quarter of 2026 at 2549.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	6.16 %	11.89 %	11.34 %	8.73 %	11.01 %
Y / Y Net Income Change	-	-	-96.94 %	-	-72.24 %
Net Income (TTM) in million	0	5	5	17	28
Return On Assets (TTM)	-0.04 %	0.87 %	1 %	3.34 %	5.5 %
CSTL's Total Ranking	# 2299	# 2549	# 1530	# 1112	# 794
Total Assets (TTM) in million	563	550	580	548	530
Seq. Total Assets Change	2.34 %	-5.29 %	5.83 %	3.5 %	7.86 %
Seq. Net Income Change	-	-	-	-	1003.07 %

CSTL's 5 Years Annual ROA >> Back to CSTL Management Effectiveness >> Compare CSTL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 13
Sector	# 213
Overall	# 2533

Return On Assets Statistics
High	Average	Low
14.57 %	-0.07 %	-9.31 %
(Dec 31 2019)		(Jun 30 2023)

Financial Statements
Castle Biosciences Inc 's Assets	$ 563 million	CSTL's Balance sheet
Castle Biosciences Inc 's Income	$ 0 million	Quarterly CSTL's Income Statement
CSTL's Income by Division		See CSTL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	11.34 %	17.9 %	1.4 %	-5.74 %	5.29 %
Total Assets in million	580	521	442	436	463
Y / Y Net Income Change	-86.55 %	-	-	-79.75 %	-
Net Income in million	5	40	0	2	9
Annual Return On Assets	0.92 %	7.64 %	-0.02 %	0.41 %	1.89 %

CSTL's 5 Years Annual ROA >> Back to CSTL Management Effectiveness >> Compare CSTL ROA to its Competitors

Comment on CSTL's ROA in the fiscal year ending 2025

In the fiscal year 2025 Castle Biosciences Inc 's ROA decreased compared to previous year to 0.92 %, due to deterioration of net income -86.55 % to $5.36 million, from $39.81 million a year ago, as CSTL's assets were $580.43 million.

More Return On Assets Ratios
CSTL's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CSTL's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CSTL's Competitors
Subscribers only: Roa for Castle Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for CSTL's Customers

You may also want to know
CSTL's Roi	CSTL's Inventory Turnover Ratio	CSTL's Growth Rates	CSTL's Dividend Comparisons
	CSTL's Profitability Ratios	CSTL's Asset Turnover Ratio	CSTL's Dividend Growth
CSTL's Roe	CSTL's Valuation Ratios	CSTL's Financial Strength Ratios	CSTL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-13T23:38:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.